论文部分内容阅读
目的 探讨系统性红斑狼疮 (SLE)患者血清中巨噬细胞来源的趋化因子 (MDC)及基质金属蛋白酶 9(MMP 9)水平与疾病活动程度的关系与意义。方法 用双抗体夹心酶联免疫吸附试验检测和比较分析 36例SLE患者和 30名健康人血清MDC及MMP 9的水平。结果 SLE患者组血清MDC和MMP 9水平 (45 1± 77ng/L ,10 9± 113μg/L)比健康对照组 (6 0 6± 2 4ng/L ,35 2± 15 5μg/L)明显降低 (均P <0 0 0 1) ;经糖皮质激素治疗后血清MDC及MMP 9浓度升高 (P <0 0 0 1和P<0 0 5 )。活动期SLE血清MDC和MMP 9水平低于非活动期 (P <0 0 0 1和P <0 0 5 ) ;肾脏损害组均明显低于非肾脏损害组 (P <0 0 0 1和P <0 0 5 )。而血清MDC水平在关节炎组明显低于非关节炎组 (P <0 0 0 1) ,但MMP 9水平差异无显著意义 (P >0 0 5 )。结论 MDC和MMP 9可能参与SLE的发病机制 ,二者的血清水平可作为反映SLE活动程度、肾脏损害以疾病进展与改善的指标。
Objective To investigate the relationship between the level of macrophage-derived chemokines (MDC) and matrix metalloproteinase 9 (MMP 9) in serum and the degree of disease activity in patients with systemic lupus erythematosus (SLE). Methods The levels of serum MDC and MMP 9 in 36 patients with SLE and 30 healthy controls were detected and compared by double antibody sandwich enzyme-linked immunosorbent assay. Results Serum levels of MDC and MMP 9 in SLE patients were significantly lower than those in healthy controls (45 ± 77ng / L, 109 ± 113μg / L) (60 ± 2 4ng / L, 35 ± 15 5μg / L) All P <0 01). The concentrations of serum MDC and MMP 9 were increased after glucocorticoid treatment (P <0.01 and P <0.05). The levels of MDC and MMP-9 in active SLE patients were lower than those in inactive patients (P <0.01 and P <0.05), and those in renal damage patients were significantly lower than those in non-renal impairment patients (P <0.01 1 and P < 0 0 5). The level of serum MDC in arthritis group was significantly lower than that in non-arthritis group (P <0.01), but the difference was not significant (P> 0.05). Conclusions MDC and MMP 9 may be involved in the pathogenesis of SLE. The serum levels of both may be used as an index to reflect the degree of SLE activity and kidney damage in terms of disease progression and improvement.